Rankings
▼
Calendar
BCRX
BioCryst Pharmaceuticals, Inc.
$2B
Q4 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$9M
Gross Profit
$7M
72.7% margin
Operating Income
-$8M
-91.1% margin
Net Income
-$5M
-50.1% margin
EPS (Diluted)
$-0.06
QoQ Revenue Growth
+15.7%
Cash Flow
Operating Cash Flow
-$6M
Free Cash Flow
-$576,000
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$90M
Total Liabilities
$88M
Stockholders' Equity
$2M
Cash & Equivalents
$22M
← FY 2016
All Quarters
Q1 2017 →
BCRX Q4 2016 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
